News & Updates

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

A second-generation robotic electromagnetic navigation (EMN) bronchoscopic platform combined with integrated digital tomosynthesis (DT) demonstrates acceptable safety and high diagnostic yield for small peripheral lung nodules, results of the first-in-human study have shown.

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024. 

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Intense rainfall appears to contribute to a higher risk of death from all causes and cardiovascular or respiratory causes, suggests a study. This association varies with local climate and urban infrastructure.

Use of the Diaphragmatic nodularity, Unilateral, Echogenicity, pleural Thickening and Septations (DUETS) score can accurately separate exudates from transudates in patients with pleural effusion (PE), reports a recent study.